Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Biotech with Heart: Atara’s Path to Hope for MS & Cancer
Tomorrow’s World Today® Podcast
22 minutes
3 months ago
Biotech with Heart: Atara’s Path to Hope for MS & Cancer
Learn more about: Atara Biotherapeutics Featured on Tomorrow's World Today: S5E3 – Healing Heroes What happens when science meets creativity at the frontier of medicine? Dr. Kristin Yarema, former Chief Commercial Officer at Atara Biotherapeutics, takes us on a journey through the world of cell therapy and its potential to transform treatment for cancer and multiple sclerosis. 🧬 Dr. Yarema shares the touching origin story of Atara, founded by Dr. Isaac Chichenover in memory of his mother, who...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
